Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

2010284 citationsJournal Articlebronze Open Access

Authors

Ronald van Vollenhoven · Karolinska University Hospital

Paul Emery · Leeds General Infirmary

Clifton O. Bingham

Edward Keystone · University of Toronto

Roy Fleischmann · The University of Texas Southwestern Medical Center

Daniel E. Furst · University of California, Los Angeles

Katherine Macey · Roche (Switzerland)

Abstract

In this longterm safety update in RA clinical trial patients, rituximab remained well tolerated over multiple courses. SAE and infections remained stable over time and by treatment course.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Rheumatoid Arthritis Research and Therapies Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Rheumatology

Volume 37, Issue 3, pp. 558-567

DOI: 10.3899/jrheum.090856

Field-Weighted Citation Impact: 16.96